Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.

Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E.

Lung Cancer. 2005 Feb;47(2):183-92.

PMID:
15639717
2.

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.

Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC.

Clin Cancer Res. 2008 May 15;14(10):3083-8. doi: 10.1158/1078-0432.CCR-07-4591.

3.

Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.

Feng JF, Wu JZ, Hu SN, Gao CM, Shi MQ, Lu ZH, Sun XC, Zhou JR, Chen BA.

Lung Cancer. 2009 Dec;66(3):344-9. doi: 10.1016/j.lungcan.2009.02.015. Epub 2009 Mar 21.

PMID:
19304340
4.

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L.

J Clin Oncol. 2004 May 15;22(10):1878-85.

PMID:
15143080
5.
6.

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.

J Clin Oncol. 2007 Jul 1;25(19):2741-6.

PMID:
17602079
7.

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC.

Pharmacogenet Genomics. 2006 Jun;16(6):429-38.

PMID:
16708051
8.

Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.

Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, Sperone P, Scagliotti G, Allolio B, Papotti M, Berruti A.

Clin Cancer Res. 2012 Jun 15;18(12):3452-61. doi: 10.1158/1078-0432.CCR-11-2692. Epub 2012 Apr 30.

9.

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.

Erčulj N, Kovač V, Hmeljak J, Franko A, Dodič-Fikfak M, Dolžan V.

Pharmacogenet Genomics. 2012 Jan;22(1):58-68. doi: 10.1097/FPC.0b013e32834e3572.

PMID:
22134350
11.

Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1).

Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC, Bepler G.

Mamm Genome. 1999 Sep;10(9):916-22.

PMID:
10441745
12.

Single nucleotide polymorphisms of IGFBP-3 gene and lung cancer risk in a Korean population.

Han SG, Park KH, Sung JS, Whang YM, Kim YJ, Shin ES, Lee JW, Lee HJ, Ryu JS, Choi IK, Seo JH, Kim YH.

Lung Cancer. 2008 Nov;62(2):152-61. doi: 10.1016/j.lungcan.2008.03.017. Epub 2008 May 2.

PMID:
18450319
14.

Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2005 Feb 15;11(4):1380-5.

15.

[A study on the relationship between RRM1 single nucleotide polymorphisms and clinical characteristics in lung cancer patients.].

Lin L, Liu X, Song S, Wang S.

Zhongguo Fei Ai Za Zhi. 2008 Dec 20;11(6):784-8. doi: 10.3779/j.issn.1009-3419.2008.06.17. Chinese.

16.

Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer.

Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M, Murakami Y.

Clin Cancer Res. 2005 Apr 15;11(8):2954-61.

17.

Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.

Wakai T, Shirai Y, Sakata J, Takamura M, Matsuda Y, Korita PV, Muneoka K, Sasaki M, Ajioka Y, Hatakeyama K.

Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1659-63. doi: 10.5754/hge11175. Epub 2011 Jul 15.

PMID:
21940346
18.

Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the -1195G > A promoter polymorphism with mild asthma.

Shi J, Misso NL, Kedda MA, Horn J, Welch MD, Duffy DL, Williams C, Thompson PJ.

Clin Exp Allergy. 2008 Jun;38(6):913-20. doi: 10.1111/j.1365-2222.2008.02986.x. Epub 2008 Apr 11.

PMID:
18489027
19.

Characterization of intron-1 haplotypes of the G protein beta 4 subunit gene--association with survival and progression in patients with urothelial bladder carcinoma.

Riemann K, Struwe H, Eisenhardt A, Obermaier B, Schmid KW, Siffert W.

Pharmacogenet Genomics. 2008 Nov;18(11):999-1008. doi: 10.1097/FPC.0b013e3283117d79.

PMID:
18815590
20.

HOP/OB1/NECC1 promoter DNA is frequently hypermethylated and involved in tumorigenic ability in esophageal squamous cell carcinoma.

Yamashita K, Kim MS, Park HL, Tokumaru Y, Osada M, Inoue H, Mori M, Sidransky D.

Mol Cancer Res. 2008 Jan;6(1):31-41. doi: 10.1158/1541-7786.MCR-07-0213.

Supplemental Content

Support Center